Jemperli

Pharma

GSK licenses Alteogen enzyme in bid to develop subQ Jemperli

With checkpoint inhibitors like Keytruda and Opdivo now sporting subQ formulations, GSK wants to ensure its own PD-1 drug doesn’t miss out on the action.

Fraiser Kansteiner Jan 20, 2026 2:26pm

GSK's Tesaro, AnaptysBio lock horns over Jemperli agreement

Nov 21, 2025 9:46am

Fierce Biotech

Anaptys plans to split into 2 businesses

Sep 30, 2025 9:35am

GSK trial result mirrors Merck's problem in ovarian cancer

Dec 20, 2024 10:46am

GSK blows Jemperli marching brass against Keytruda with new nod

Aug 1, 2024 3:00pm

Merck's Keytruda misses the mark in endometrial cancer study

May 9, 2024 10:55am